BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

Propelled by growing understanding of their biology, and an expression pattern that goes well beyond T cells, SIGLEC proteins are rising as the next set of checkpoint targets to challenge PD-1. The sugar-binding proteins could...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

The rush to drug CD47 shows no signs of abating, with five companies launching clinical programs for cancer this year and three moving forward on the back of encouraging Phase I data. The differentiator may...
BC Innovations | Aug 8, 2019
Distillery Therapeutics

Blocking interaction between 'don't eat me signal' CD24 and SIGLEC10 to treat cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer; breast cancer A team led by FortySeven Inc. founder Irving Weissman showed inhibiting the interaction between CD24 on cancer cells and SIGLEC10 on tumor-associated macrophages (TAMs) could treat ovarian...
BC Extra | Aug 1, 2019
Preclinical News

Forty Seven sees combo opportunities for Weissman's latest ‘don't eat me’ signal

Forty Seven believes the latest study from founder Irving Weissman could point to combination strategies for blocking “don’t eat me signals” on tumors, but thinks inhibitors of the CD24-SIGLEC10 interaction described in the paper will...
BC Innovations | Dec 13, 2017
Distillery Therapeutics


INDICATION: Pancreatic cancer Patient sample and cell culture studies suggest inhibiting KMT5C could help treat pancreatic cancer. In tumor samples from pancreatic cancer patients, KMT5C expression was higher in invasive tumors than in adjacent normal...
BC Extra | Dec 11, 2017
Preclinical News

Histone modifier is implicated in epithelial-mesenchymal transition

In a paper published in the Journal of Cell Biology , researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) identified a histone modifier that may regulate epithelial-mesenchymal transition (EMT), a process associated with tumor...
BC Extra | Jan 13, 2017
Financial News

OncoImmune raises $15M in series A

OncoImmune Inc. (Rockville, Md.) said it raised $15 million in a series A round led by 3E Bioventures Capital. The company's lead candidate, CD24Fc , is in a Phase II study to prevent graft versus host...
BC Innovations | May 22, 2014
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Nano-plasmonic exosome (nPLEX) sensor for high throughput, label-free, quantitative analysis of exosome proteins Patient sample studies suggest an nPLEX sensor can help diagnose and/or...
BC Innovations | Apr 17, 2014
Targets & Mechanisms

Unfolding triple-negative breast cancer

A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers-overactivation of the transcription factor X-box binding protein 1 -that could open the door to new therapies for this notoriously...
BC Innovations | Apr 28, 2011
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer CD24 Studies in patient samples and in mice suggest that inhibiting CD24 could help treat metastatic bladder cancer. In...
Items per page:
1 - 10 of 18